XAIR Form 4: CFO option repricing to $1.95 effective Nov 4, 2025

Q: What did Beyond Air (XAIR) disclose in this Form 4?

An option repricing for the CFO effective November 4, 2025 , reducing the exercise price to $1.95 while keeping other terms unchanged.

Q: What is the new exercise price for the repriced options of XAIR’s CFO?

The exercise price was set at $1.95 per share , the closing price on November 3, 2025 .

Q: Which prior option exercise prices were affected?

Options previously priced at $10.80 and $5.892 were repriced to $1.95 .

Q: How many derivative securities does the CFO own after the transactions?

The filing lists 47,500 derivative securities beneficially owned, held directly .

Q: Under what plan were the options issued?

They were issued under the Amended and Restated 2013 Equity Incentive Plan .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Beyond Air (XAIR) reported insider activity on a Form 4 detailing an option repricing for its Chief Financial Officer effective November 4, 2025. The exercise price of certain stock options was reduced to $1.95 per share, the closing price of the company’s common stock on November 3, 2025. All other terms of the options remain unchanged.

The filing shows cancellations of options previously priced at $10.80 and $5.892 and grants at $1.95 in equivalent amounts, including 15,000, 6,000, 3,750, 1,000, and 17,500 options. Following the reported transactions, the CFO beneficially owns 47,500 derivative securities directly. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and will vest per the original award agreements, subject to continued service.

Insider Trade Summary

10 transactions reported

Mixed 10 txns

Insider Larson Douglas Quinton

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Disposition	Stock Options (Right to buy)	15,000	$0.00	--
Grant/Award	Stock Options (Right to buy)	15,000	$0.00	--
Disposition	Stock Options (Right to buy)	6,000	$0.00	--
Grant/Award	Stock Options (Right to buy)	6,000	$0.00	--
Disposition	Stock Options (Right to buy)	1,000	$0.00	--
Grant/Award	Stock Options (Right to buy)	1,000	$0.00	--
Disposition	Stock Options (Right to buy)	3,750	$0.00	--
Grant/Award	Stock Options (Right to buy)	3,750	$0.00	--
Disposition	Stock Options (Right to buy)	17,500	$0.00	--
Grant/Award	Stock Options (Right to buy)	17,500	$0.00	--

Holdings After Transaction: Stock Options (Right to buy) — 0 shares (Direct)

Footnotes (1)

On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

11/06/2025 - 09:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Larson Douglas Quinton

(Last)

(First)

(Middle)

C/O BEYOND AIR, INC.

900 STEWART AVENUE, SUITE 301

(Street)

GARDEN CITY

11530

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Beyond Air, Inc. [ XAIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to buy)	$10.8	11/04/2025		D⁽¹⁾			15,000	⁽²⁾	⁽²⁾	Common Stock	15,000	⁽¹⁾	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A⁽¹⁾		15,000		⁽²⁾	⁽²⁾	Common Stock	15,000	⁽¹⁾	15,000	D
Stock Options (Right to buy)	$10.8	11/04/2025		D⁽¹⁾			6,000	⁽²⁾	⁽²⁾	Common Stock	6,000	⁽¹⁾	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A⁽¹⁾		6,000		⁽²⁾	⁽²⁾	Common Stock	6,000	⁽¹⁾	6,000	D
Stock Options (Right to buy)	$10.8	11/04/2025		D⁽¹⁾			1,000	⁽²⁾	⁽²⁾	Common Stock	1,000	⁽¹⁾	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A⁽¹⁾		1,000		⁽²⁾	⁽²⁾	Common Stock	1,000	⁽¹⁾	1,000	D
Stock Options (Right to buy)	$10.8	11/04/2025		D⁽¹⁾			3,750	⁽²⁾	⁽²⁾	Common Stock	3,750	⁽¹⁾	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A⁽¹⁾		3,750		⁽²⁾	⁽²⁾	Common Stock	3,750	⁽¹⁾	3,750	D
Stock Options (Right to buy)	$5.892	11/04/2025		D⁽¹⁾			17,500	⁽²⁾	⁽²⁾	Common Stock	17,500	⁽¹⁾	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A⁽¹⁾		17,500		⁽²⁾	⁽²⁾	Common Stock	17,500	⁽¹⁾	47,500	D

Explanation of Responses:

1. On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged.

2. This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

	/s/ Douglas Quinton Larson	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Beyond Air (XAIR) disclose in this Form 4?

An option repricing for the CFO effective November 4, 2025, reducing the exercise price to $1.95 while keeping other terms unchanged.

What is the new exercise price for the repriced options of XAIR’s CFO?

The exercise price was set at $1.95 per share, the closing price on November 3, 2025.

Which prior option exercise prices were affected?

Options previously priced at $10.80 and $5.892 were repriced to $1.95.

How many derivative securities does the CFO own after the transactions?

The filing lists 47,500 derivative securities beneficially owned, held directly.

Under what plan were the options issued?

They were issued under the Amended and Restated 2013 Equity Incentive Plan.

Do the vesting terms change with the repricing?

No. Vesting continues per the original award agreements, subject to continued service.